ERBB2 and endometrial cancer: Furthermore, even in the absence of co-amplification of CCNE1 or ERBB2, MECOM amplification alone conferred a similar two-fold increase in risk, suggesting that MECOM amplification may independently identify an aggressive subset of endometrial cancers.